Ads
related to: her2 positive brain metastases survival- Clinical Trial Results
Learn About Clinical Trial Results
In Patients Like Yours.
- Request A Rep
Request a Representative & Discover
More About Treatment Option.
- Prescription Info
Find Dosing Guides & Safety
Information Here.
- Clinical Trial Design
Learn More About Clinical Trial
And Study Results Today.
- Clinical Trial Results
Search results
Results From The WOW.Com Content Network
Tucatinib is a kinase inhibitor indicated in combination with trastuzumab and capecitabine for the treatment of adults with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. [3]
Anti-HER2 antibody. HER2-positive breast cancer, gastric cancer, pancreatic cancer (orphan) and gastro-oesophageal junction cancer. Cardiac dysfunction, infusion-related reactions, peripheral neuropathy and pulmonary toxicity (rare). 2.2 Tyrosine kinase inhibitor: Afatinib: PO: EGFR, HER2 and HER4 inhibitor. Non-small cell lung cancer.
In particular, she worked on HER2 positive breast cancer and breast cancer patients with brain metastasis. [5] [6] [7] Lin has developed novel pharmaceuticals for patients whose breast cancer has spread to the brain. [3] [8] Cancer-related central nervous system and brain
HER2 is the target of the monoclonal antibody trastuzumab (marketed as Herceptin). Trastuzumab is effective only in cancers where HER2 is over-expressed. One year of trastuzumab therapy is recommended for all patients with HER2-positive breast cancer who are also receiving chemotherapy. [33] Twelve months of trastuzumab therapy is optimal.
A brain metastasis is a cancer that has metastasized (spread) to the brain from another location in the body and is therefore considered a secondary brain tumor. [ 1 ] [ 2 ] The metastasis typically shares a cancer cell type with the original site of the cancer. [ 3 ]
Histologic factors associated with worse prognosis include high histologic grade, hormone receptor negativity, and HER2 negativity. Regarding genetic risk factors, BRCA1-associated breast cancers may have higher rates of lung and brain metastases but a lower rate of bone metastases.
Ads
related to: her2 positive brain metastases survival